DC/NK Cell Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 2, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Lung Cancer (NSCLC)
Interventions
BIOLOGICAL

In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer

The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use.

Trial Locations (1)

640

RECRUITING

National Taiwan University Hospital Yunlin Branch, Huwei

All Listed Sponsors
collaborator

National Taiwan University Hospital, Yun-Lin Branch

OTHER

lead

National Taiwan University Clinical Trial Center

OTHER